Sunitinib in Never-Smokers With Lung Adenocarcinoma

Inclusion Criteria:

Histologically or cytologically confirmed advanced (stage IV or recurrent) non-small cell lung cancer
Adenocarcinoma histology of any variant, including adenosquamous histology
Wild-type for mutations in EGFR, KRAS and ALK
Must have < 100 cigarettes smoked lifetime OR known to harbor a RET rearrangement OR another potentially targetable genomic alteration as defined per protocol
Disease must be measureable per RECIST 1.1
At least one prior systemic therapy (adjuvant or palliative)
18 years or older
Life expectancy of greater than 4 weeks
Adequate ECOG performance status 0 or 1
Adequate organ function as defined in the protocol
Adequate tumor tissue for the correlative analyses on study, or must undergo a biopsy to obtain adequate tissue

Exclusion Criteria:

Pregnant or breastfeeding
Chemotherapy within 4 weeks of entering study, or lack of recover from adverse events to grade 1 or less due to systemic agents administered more than 4 weeks earlier
Radiation therapy within 2 weeks prior to entering study
Major surgery within 4 weeks prior to entering the study
Receiving any other investigational agents
Known untreated, symptomatic or progressive brain metastases; presence of carcinomatous meningitis; history of intracranial hemorrhage or brain metastases requiring chronic steroids
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
Use of certain inhibitors and inducers of CYP3A4
Grade 3 or 4 hemoptysis or hemorrhage within 4 weeks prior to study entry
History of significant bleeding disorder unrelated to cancer
Poorly controlled hypertension
Severe cardiovascular disease
Prolongation of corrected QT interval
History of a different malignancy except: cervical cancer in situ, basal or squamous cell carcinoma of the skin, low risk centralized prostate cancer
HIV positive on combination antiretroviral therapy